Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Transcarent

Health Tech & Medtech · San Francisco, United States · Founded 2020 Unicorn

New consumer-directed health and care platform for employees of self-insured employers and their families

Valuation
$1–2.5B
Latest valuation · 2026
Unlock exact value
Revenue
$100–500M
Latest reported FY
Unlock exact value
Headcount
500–1k
Current team size
Unlock exact value

Investors

17 investors on Transcarent's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage
General Catalyst
7wire Ventures
Alta Partners
Jove Equity Partners
Series B+ 13 investors entered at this stage
Leaps by Bayer
Intermountain Healthcare
Threshold Ventures
Memorial Hermann Health System
GreatPoint Ventures
Geodesic Capital
Merck Global Health Innovation Fund
Kleiner Perkins
Ally Bridge Group
Human Capital
Kinnevik
Rush University Medical Center
Northwell Health

Global footprint

Where Transcarent has talent and traffic

AI talent share
1.9% of workforce is AI talent
(14 of 731 staff)
Core AI40.55%
Other AI101.37%
Non-AI workforce71798.08%
Workforce by country
6 countries with
team presence
🇺🇸 United States97.1%
🇨🇿 Czech Republic0.9%
🇲🇽 Mexico0.8%
🇷🇸 Serbia0.5%
🇨🇦 Canada0.5%
Top 5 of 6 shown
Web traffic by country
45K monthly visits
across markets
🇺🇸 United States92%
🇮🇳 India2.7%
🇬🇧 United Kingdom2%
🇨🇦 Canada1.6%
🇩🇪 Germany0.7%
Top 5 markets shown

Capital deployed

Transcarent's 3 investments and acquisitions.

Every disclosed deal where Transcarent appeared as a backer or acquirer, 2020–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Transcarent's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Transcarent's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Transcarent

        An AI-synthesized read of the highest-engagement posts about Transcarent on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Transcarent on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.